Global Hypercalcemia Treatment Market 2017-2021


◆タイトル:Global Hypercalcemia Treatment Market 2017-2021
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆資料形式:PDF / 英語
Single User(1名利用)USD3,500 ⇒換算¥395,500見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥565,000見積依頼/購入/質問フォーム
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。





ABSTRACTAbout Hypercalcemia Treatment

Hypercalcemia is a condition in which the calcium level in the blood is above normal. Too much calcium in the blood can weaken the bones, create stones in the kidneys, and interfere with the functioning of the heart and the brain. Hypercalcemia refers to the condition where too much calcium enters the extracellular fluid or when there is insufficient calcium excretion from the kidneys. The cases of hypercalcemia are mainly caused by malignancy or hyperparathyroidism. Hypercalcemia is an outcome of overactive parathyroid glands. These four tiny glands are located near thyroid gland and each of them are about the size of a rice grain.

Technavio’s analysts forecast the global hypercalcemia treatment market to grow at a CAGR of 5.44% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global hypercalcemia treatment market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:
• Americas

Technavio’s report, Global Hypercalcemia Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• AbbVie
• Amgen
• Merck
• Novartis
• OPKO Health

[Other prominent vendors]
• DiaSorin
• Rockwell Medical
• Kyowa Hakko Kirin
• Fujirebio

[Market driver]
• Expanding label indications.
• For a full, detailed list, view our report

[Market challenge]
• Severe threat of damage to nervous system.
• For a full, detailed list, view our report

[Market trend]
• Growing focus on emerging economies.
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.


Table of Contents
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
• Key market highlights

PART 05: An overview of Hypercalcemia

PART 06: Pipeline Analysis

PART 07: Market landscape
• Market overview
• Five forces analysis

PART 08: Market segmentation by product type
• Bisphosphonates
• Glucocorticoids
• Calcimimetic agents
• Others

PART 09: Market segmentation by geography
• Hypercalcemia treatment market in Americas
• Hypercalcemia treatment market in EMEA
• Hypercalcemia treatment market in APAC

PART 10: Decision framework

PART 11: Drivers and challenges
• Market drivers
• Impact of drivers on key customer segments
• Market challenges
• Impact of challenges on key customer segments

PART 12: Market trends
• Combination therapy
• Increase in outsourcing
• Growing focus on emerging economies

PART 13: Vendor landscape
• Competitive scenario

PART 14: Key vendor analysis
• AbbVie
• Amgen
• Merck
• Novartis
• OPKO Health
• Other prominent vendors

PART 15: Appendix
• List of abbreviations

[List of Exhibits]

Exhibit 01: Body parts affected by high calcium
Exhibit 02: Pipeline landscape
Exhibit 03: Global hypercalcemia treatment market snapshot
Exhibit 04: Global hypercalcemia treatment market 2016-2021 ($ millions)
Exhibit 05: Opportunity analysis in global hypercalcemia treatment market
Exhibit 06: Five forces analysis
Exhibit 07: Market segmentation by product type 2016
Exhibit 08: Bisphosphonates segment 2016-2021 ($ millions)
Exhibit 09: Glucocorticoids segment 2016-2021 ($ millions)
Exhibit 10: Calcimimetic agents segment 2016-2021 ($ millions)
Exhibit 11: Global hypercalcemia treatment market by geography 2016 and 2021
Exhibit 12: Global hypercalcemia treatment market revenue by geography 2016-2021 ($ millions)
Exhibit 13: Market scenario in Americas
Exhibit 14: Hypercalcemia treatment market in Americas ($ millions)
Exhibit 15: Market scenario in EMEA
Exhibit 16: Hypercalcemia treatment market in EMEA ($ millions)
Exhibit 17: Market scenario in APAC
Exhibit 18: Hypercalcemia treatment market in APAC ($ millions)
Exhibit 19: Key approvals
Exhibit 20: Key factors driving the market growth
Exhibit 21: Impact of drivers
Exhibit 22: Impact of serum calcium concentration
Exhibit 23: Impact of challenges
Exhibit 24: Competitive structure analysis of global hypercalcemia treatment market 2016
Exhibit 25: Competitive analysis of global hypercalcemia market
Exhibit 26: AbbVie: Key highlights
Exhibit 27: AbbVie: Strength assessment
Exhibit 28: AbbVie: Strategy assessment
Exhibit 29: AbbVie: Opportunity assessment
Exhibit 30: Amgen: Key highlights
Exhibit 31: Amgen: Strength assessment
Exhibit 32: Amgen: Strategy assessment
Exhibit 33: Amgen: Opportunity assessment
Exhibit 34: Merck: Key highlights
Exhibit 35: Merck: Strength assessment
Exhibit 36: Merck: Strategy assessment
Exhibit 37: Merck: Opportunity assessment
Exhibit 38: Novartis: Strength assessment
Exhibit 39: Novartis: Strategy assessment
Exhibit 40: Novartis: Opportunity assessment
Exhibit 41: OPKO Health: Key highlights
Exhibit 42: OPKO Health: Strength assessment
Exhibit 43: OPKO Health: Strategy assessment
Exhibit 44: OPKO Health: Opportunity assessment


AbbVie, Amgen, Merck, Novartis, OPKO Health, DiaSorin, Rockwell Medical, Kyowa Hakko Kirin, and Fujirebio.